Meadow Creek Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Meadow Creek Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$454K	Hold	5,644	–	–	0.01%	749
2019 Q2	$410K	Sell	5,644 -1,020	-15%	-$78.3K	0.01%	787
2019 Q1	$623K	Sell	6,664 -68	-1%	-$5.69K	0.01%	608
2018 Q4	$491K	Sell	6,732 -64,770	-91%	-$4.98M	0.01%	628
2018 Q3	$6.26M	Sell	71,502 -7,174	-9%	-$722K	0.12%	165
2018 Q2	$7.75M	Buy	78,676 +18,802	+31%	+$1.86M	0.16%	128
2018 Q1	$7.13M	Buy	+59,874	New	+$7.72M	0.15%	137

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Meadow Creek Investment Management's ALNY Position: Q3 2019 in Review

Meadow Creek Investment Management held its Alnylam Pharmaceuticals (ALNY) position steady in Q3 2019 at 5,644 shares worth $454K. The position accounts for 0.01% of the portfolio, ranked #749.

Meadow Creek Investment Management first reported a position in ALNY in Q1 2018 and has held it in 7 quarters since. The position peaked at $7.75M in Q2 2018. 281 funds tracked by Wall St. Rank hold ALNY as of Q3 2019.

Meadow Creek Investment Management held 5,644 shares of Alnylam Pharmaceuticals worth $454K as of Q3 2019.
Meadow Creek Investment Management left its Alnylam Pharmaceuticals share count unchanged in Q3 2019.
Alnylam Pharmaceuticals made up 0.01% of Meadow Creek Investment Management's portfolio in Q3 2019, its #749 holding.
Meadow Creek Investment Management first reported a position in Alnylam Pharmaceuticals in Q1 2018 and has held it in 7 quarters since.
Meadow Creek Investment Management's Alnylam Pharmaceuticals position peaked at $7.75M in Q2 2018.
281 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2019.

Based on Meadow Creek Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.